China Health Strategic Industry Trend Tracking and Investment Decision Suggestion Report 2024-2030
[Publisher]: Zhongying Xinhe Research Network
[The content part has been deleted, and the details can be found in the full information published by Zhongying Xinhe Research Network!]
Chapter 1: Overview of the development of the big health strategy
1.1 Definitions related to the big health strategy
1.1.1 General health
1.1.2 Big health industry
1.1.3 Big Health Strategy
1.2 Research Scope and Analysis Methods of Big Health Strategy
1.2.1 Scoping of the report
1.2.2 Introduction to Report Analysis Methods
1.3 Analysis of the benefits of the big health strategy
1.3.1 Economic benefits
(1) The format of the pharmaceutical industry has changed
(2) Pharmacies seek innovative development models
(3) The industry has broad prospects
1.3.2 Social benefits
1.3.3 Marketing Effectiveness
Chapter 2: Analysis of the environment for the development of the big health strategy
2.1 Analysis of the economic environment of the big health strategy
2.1.1 Current status and outlook of the economic environment
(1) The current situation of the domestic macroeconomic environment
(2) The development status of the domestic pharmaceutical industry
(3) The current situation of domestic residents' income level
(4) Domestic macroeconomic indicators
2.1.2 Review of the impact on the big health strategy
2.2 Analysis of the social environment of the big health strategy
2.2.1 Analysis of relevant social factors
(1) Demographic changes
(2) Changes in the ecological environment
and (3) changes in medical costs
(4) Food safety issues
(5) Drug safety issues
(6) National health awareness
(7) Urbanization factors
2.2.2 Review of the impact on the big health strategy
2.3 Analysis of the policy environment of the big health strategy
2.3.1 Regulatory regime
2.3.2 Interpretation of relevant policies
2.3.3 Review of the impact on the big health strategy
Chapter 3: Analysis of the Development Status and Trend of the Big Health Strategy
3.1 The current situation and experience enlightenment of the international health industry
3.1.1 Overview of international developments
(1) The history of the international health industry
(2) The scale of the international health industry
(3) The structure of the international health industry
(4) Segmentation of the international health industry
3.1.2 Analysis of international leading cases
(1)雅培(Abbott)
（2）强生（Johnson&Johnson）
(3)诺华(Novartis AG)
(4) 克(Glaxo Smith Kline)
(5)赛诺菲-安万特(Sanofi-Aventis)
3.1.3 Lessons from international development experience
3.2 Analysis of the implementation status of the domestic health strategy
3.2.1 Development History
3.2.2 Pharmaceutical manufacturing enterprises
(1) Analysis of the development status of pharmaceutical companies
(2) Overview of the big health strategy of pharmaceutical companies
(3) The main advantages of the big health strategy of pharmaceutical companies
(4) Typical case analysis of pharmaceutical companies' big health strategy
(5) Summary of experience in trying to achieve big health strategy of pharmaceutical companies
3.2.3 Pharmaceutical sales enterprises
(1) Analysis of the development status of pharmacies
(2) Overview of the big health strategy of pharmacies
(3) The main advantages of the pharmacy's big health strategy
(4) Typical case analysis of pharmacy big health strategy
(5) Summary of experience in trying the big health strategy of pharmacies
3.3 Analysis of the development trend of the domestic health industry
3.3.1 Policy trends
3.3.2 Product Trends
3.3.3 Demand Trends
Chapter 4: Analysis of the development model of the big health strategy
4.1 Horizontal expansion pattern analysis
4.1.1 Overview of the Horizontal Expansion Model
4.1.2 Horizontal expansion analysis (key products)
(1) Nutrition and health care
(2) Functional skin care products
(3) Medical devices
(4) Daily chemicals
4.1.3 Horizontal Expansion Analysis (Key Firms)
(1) The status quo of horizontal expansion
(2) Horizontal expansion cases
4.2 Longitudinal extension mode analysis
4.2.1 Overview of the longitudinal extension mode
4.2.2 Analysis of longitudinal extension mode (key mode)
(1) Distribution model
(2) Direct sales model
(3) E-commerce model
4.2.3 Vertical Expansion Analysis (Key Enterprises)
(1) The status quo of vertical expansion
(2) Cases of vertical expansion
Chapter 5: Typical Case Analysis of Big Health Strategy
5.1 Overall overview analysis of typical cases of big health strategy
5.1.1 Leading pharmaceutical companies as a whole enter the big health
5.1.2 Pharmacies accelerate their integration into online layout
(1) The proportion of sales of the top 10 pharmacies in single-store health products
(2) Changes in the profit contribution rate of big health products of the top 100 pharmacies
(3) Leading chain pharmacies to accelerate their online business layout
5.2 Typical case analysis of pharmaceutical companies' big health strategies
5.2.1 Analysis of Yunnan Baiyao Group Co., Ltd.'s big health strategy
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
(7) Analysis of corporate investment, mergers and acquisitions
(8) Analysis of the latest development trends of enterprises
5.2.2 Analysis of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.'s big health strategy
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
(7) Analysis of corporate investment, mergers and acquisitions
(8) Analysis of the latest development trends of enterprises
5.2.3 Analysis of Tasly Pharmaceutical Group Co., Ltd.'s big health strategy
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
(7) Analysis of the latest development trends of the enterprise
5.2.4 Analysis of Ma Yinglong Pharmaceutical Group Co., Ltd.'s big health strategy
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
(7) Analysis of the latest development trends of the enterprise
5.2.5 Analysis of the big health strategy of Harbin Pharmaceutical Group Renmin Tongtai Pharmaceutical Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
(7) Analysis of the latest development trends of the enterprise
5.2.6 Analysis of the big health strategy of Beijing Tong Ren Tang Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
(7) Analysis of the latest development trends of the enterprise
5.2.7 Analysis of the big health strategy of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of the company's operation
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.2.8 Revised the analysis of the big health strategy of Pharmaceutical Group Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.2.9 Analysis of the big health strategy of Zhongjing Wanxi Pharmaceutical Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.2.10 Analysis of the big health strategy of Dianhong Pharmaceutical Group Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.2.11 Analysis of the big health strategy of Zhejiang Kangenbei Pharmaceutical Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.2.12 Analysis of Kangmei Pharmaceutical Co., Ltd.'s big health strategy
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.2.13 Analysis of Guizhou Yibai Pharmaceutical Co., Ltd.'s big health strategy
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.2.14 Analysis of the big health strategy of Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd
(1) A brief introduction to the development of the enterprise
(2) Analysis of corporate health strategy
(3) Analysis of the corporate health market
(4) Analysis of enterprise health products
(5) Analysis of business operations
(6) Analysis of the advantages and disadvantages of the company's big health strategy
5.3 Typical case analysis of pharmacy health strategy
5.3.1 Analysis of the big health strategy of Xi'an Yikang Pharmaceutical Chain Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) Analysis of the development of enterprise health strategy
(4) The product structure of the enterprise
(5) Analysis of business operations
(6) The number and distribution of enterprise stores
(7) Enterprise market expansion analysis
(8) Enterprise suppliers and procurement
(9) Analysis of the advantages and disadvantages of the company's big health strategy
5.3.2 Analysis of the big health strategy of Yixintang Pharmaceutical Group Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) Analysis of the development of enterprise health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of the company's big health strategy
5.3.3 Analysis of the operation of Gansu Zhongyou Health Pharmaceutical Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) Analysis of the development of enterprise health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of the company's big health strategy
5.3.4 Analysis of the big health strategy of Sinopharm Guoda Pharmacy Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) Analysis of the development of enterprise health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of the company's big health strategy
5.3.5 Anhui Fengyuan Pharmacy Chain Co., Ltd. Health Strategy Analysis
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) Analysis of the development of enterprise health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of the company's big health strategy
5.3.6 Analysis of the big health strategy of Hunan Qianjin Pharmacy Chain Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) Analysis of the development of enterprise health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of enterprise management
5.3.7 Analysis of the big health strategy of Shanghai Hua's Pharmacy
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) The development strategy of the company's big health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of enterprise management
5.3.8 Analysis of the big health strategy of Dashenlin Pharmaceutical Group Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) Analysis of the development of enterprise health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of the company's big health strategy
5.3.9 Analysis of the big health strategy of the People's Pharmacy Chain Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) The development of the company's big health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of the company's big health strategy
5.3.10 Analysis of the big health strategy of Yifeng Pharmacy Chain Co., Ltd
(1) Brief analysis of enterprise development
(2) Enterprise positioning and service objects
(3) The development of the company's big health strategy
(4) Analysis of business conditions
(5) The number and distribution of enterprise stores
(6) Enterprise market expansion analysis
(7) Enterprise suppliers and procurement
(8) Analysis of the advantages and disadvantages of the company's big health strategy
Chapter 6: Recommendations for the development of the big health strategy
6.1 Analysis of opportunities for the transformation of the big health strategy
6.1.1 Analysis of the advantages of pharmaceutical companies' big health strategies
(1) Brand advantage
(2) Product quality advantages
(3) Advertising and marketing advantages
6.1.2 Analysis of the advantages of the pharmacy's big health strategy
6.1.3 Opportunity analysis of the big health strategy
(1) Population drivers
(2) Economic drivers
(3) Technology drivers
(4) Environmental drivers
6.2 Risk analysis of the transformation of the big health strategy
6.2.1 Product Security Risks
6.2.2 Market Change Risk
6.2.3 Own business risks
6.2.4 Risk of product homogenization
6.3 Necessary qualities for the transformation of the big health strategy
6.3.1 Analysis of the necessary qualities for the development of big health strategy of pharmaceutical companies
6.3.2 Analysis of the necessary qualities of pharmacies to develop a big health strategy
6.4 Forward-looking suggestions for the transformation of the big health strategy
6.4.1 Suggestions on the big health strategy of pharmaceutical companies
6.4.2 Suggestions on the strategy of pharmacy health
Table of Contents of Charts
Chart 1: General Health Category
Figure 2: Classification of the big health industry
Figure 3: Analysis architecture diagram of the big health strategy report
Figure 4: China's GDP from 2011 to 2023 (unit: 100 million yuan, %)
Figure 5: Per capita GDP and growth rate of mainland residents from 2018 to 2023 (unit: yuan, %)
Figure 6: Scale and growth of China's pharmaceutical industry from 2019 to 2023 (unit: 100 million yuan)
Figure 7: Total profit and growth of China's pharmaceutical industry from 2018 to 2023 (unit: 100 million yuan, yuan, %)
Figure 8: Per Capita Disposable Income and Growth Rate of Chinese Residents, 2018-2023 (Unit: RMB, %)
Figure 9: Per Capita Disposable Income of Urban and Rural Residents in China, 2018-2023 (Unit: RMB)
Figure 10: China's health expenditure and its growth from 2018 to 2023 (unit: 100 million yuan, yuan, %)
Chart 11: Growth of Key Economic Indicators, 2019-2023 (in %)
Figure 12: Number and proportion of population aged 65 and above in mainland China from 2018 to 2023 (unit: 10,000 people, %)
Figure 13: Ambient air quality compliance in 337 cities in 2023
Figure 14: Overall water quality status of river basins across the country in 2023
Figure 15: Trend chart of average outpatient expenses of hospitals in mainland China from 2009 to 2023 (unit: yuan)
Figure 16: Review of major domestic food safety events from 2018 to 2023
Exhibit 17: Survey results of the survey on what matters most to the surveyed public in 2023 (in %)
Exhibit 18: Results of the 2023 Public Health Distress Survey (Unit: %)
Figure 19: Changes in China's urbanization rate from 2018 to 2023 (unit: %)
Exhibit 20: List of the impact of social factors on the big health strategy
Exhibit 21: Regulatory Authorities and Main Functions of China's Big Health Industry
Exhibit 22: Policies related to the big health industry
Figure 23: China's "three-medicine linkage" pattern
Exhibit 24: U.S. National Health Spending Scale and Projections, 2024-2030 (in $100 million)
Chart 25: Share of GDP of the U.S. non-government production sector by industry in 2023 (unit: %)
Exhibit 26: U.S. Health Industry Structure (Unit: %)
Exhibit 27: Chart of China's Big Health Industry Structure (Unit: %)
Exhibit 28: Presentation of Home Health Services in the United States
Exhibit 29: Analysis of key economic indicators of Abbott (Abbott) from 2018 to 2023 (in USD billion)
Exhibit 30: List of Abbott's big health products
Exhibit 31: Strategic cooperation between Abbott at the 3rd CIIE
图表32：强生（Johnson&Johnson）基本信息表
Exhibit 33: Sales revenue of Johnson & Johnson (JNJ) from 2018 to 2023 (unit: $100 million, %)
Exhibit 34: Johnson & Johnson sales revenue by region in 2023 (in billions, %)
Exhibit 35: Johnson & Johnson operating conditions, 2019-2023 (USD billions)
Exhibit 36: Johnson & Johnson's business structure and revenue (in billions, %)
Exhibit 37: Johnson & Johnson product mix
Exhibit 38: Novartis AG Basic Information Sheet
Exhibit 39: Key economic indicators of Novartis AG, 2018-2023 (in USD billion)
Exhibit 40: Novartis AG's revenue by region in Q4 2023 (in USD billion, %)
Exhibit 41: Novartis AG product mix
Exhibit 42: Novartis AG's business in China
Exhibit 43: Glaxo Smith Kline Basic Information Table
Exhibit 44: Key economic indicators of Glaxo Smith Kline, 2018-2023 (in GBP billion)
Exhibit 45: Changes in GSK's main revenues from 2018 to 2023 (unit: GBP billion, %)
Exhibit 46: Glaxo Smith Kline's product mix, by revenue (GBP billion, %) 2018-2023
Exhibit 47: Sanofi-Aventis Basic Information Sheet
Exhibit 48: Sanofi Aventis main operating indicators from 2018 to 2023 (in euros billion, %)
Exhibit 49: Key economic indicators of Sanofi-Aventis, 2018-2023 (in EUR billion)
Exhibit 50: Sanofi-Aventis product mix, 2018-2023 - by revenue (in euros billion, %)
Exhibit 51: Global Consumer Healthcare Products Market Size, 2024-2030 (in USD billion)
Figure 52: Breakdown of China's big health industry investment in the first half of 2019-2023 (unit: 100 million yuan)
Exhibit 53: Breakdown of cumulative transaction size in the digital health sector from 2018 to the first half of 2023 (unit: 100 million yuan)
Exhibit 54: Time to entry of leading international pharmaceutical companies in China
Figure 55: Schematic diagram of the domestic development process of the big health strategy
Figure 56: Growth rate of added value of pharmaceutical manufacturing industry from 2018 to 2023 (unit: %)
Exhibit 57: Analysis of China's total imports and exports of pharmaceuticals and trade deficit in mainland China, 2018-2023 (unit: US$100 million)
Figure 58: Analysis of China's pharmaceutical import volume and growth rate from 2018 to 2023 (unit: 10,000 tons, %)
Figure 59: Analysis of China's pharmaceutical import value and growth rate from 2018 to 2023 (unit: 10,000 tons, %)
Figure 60: Analysis of China's pharmaceutical export value and growth rate from 2018 to 2023 (unit: 10,000 tons, %)
Chart 61: Growth of fixed assets in China's pharmaceutical industry from 2019 to 2023 (unit: %)
Exhibit 62: List of pharmaceutical companies' big health strategies
Figure 63: The initial stage of Yunnan Baiyao toothpaste has been questioned by many
Exhibit 64: Research findings from Yunnan Baiyao toothpaste marketing team
Exhibit 65: Top three barriers to the purchase of Baiyao toothpaste in Yunnan
Figure 66: Three major expansions of Yunnan Baiyao toothpaste
Figure 67: Channel strategy of Yunnan Baiyao toothpaste
Exhibit 68: Hype strategy for Yunnan Baiyao toothpaste
Exhibit 69: TV advertising strategy for Yunnan Baiyao toothpaste
Figure 70: Summary of the successful experience of Yunnan Baiyao toothpaste
Exhibit 71: List of key factors for the success or failure of pharmaceutical companies' big health strategies
Exhibit 72: Size and growth of China's pharmaceutical retail market from 2019 to 2023 (unit: 100 million yuan, %)
Exhibit 73: Revenue of China's four major listed pharmacy chains from 2019 to 2023 (unit: 100 million yuan)
Figure 74: Changes in the number of pharmaceutical business enterprises in China from 2018 to 2023 (unit: 10,000 units, %)
Exhibit 75: Changes in the number of chain pharmacy enterprises in China from 2018 to 2023 (unit: households, %)
Exhibit 76: Changes in the number of chain pharmacies in China from 2018 to 2023 (unit: 10,000 stores, %)
Exhibit 77: Number and growth of retail pharmacies from 2018 to 2023 (unit: 10,000 units)
Exhibit 78: Regional distribution of China's retail drug sales in 2023 (unit: %)
Exhibit 79: List of Pharmacy Big Health Strategies
Exhibit 80: List of key factors for the success or failure of a pharmaceutical company's big health strategy
Figure 81: 2018-2023 China health care products industry market size trend chart (unit: 100 million yuan, %)
Exhibit 82: Market share of China's health care products companies in 2023 (unit: %)
Exhibit 83: China's functional skincare market size and forecast from 2024 to 2030 (unit: 100 million yuan)
Figure 84: Competitive level of China's cosmeceutical market
Exhibit 85: Analysis of China's leading listed companies in the cosmeceutical industry in 2023 (unit: 100 million yuan)
Figure 86: Growth of the total scale of the medical device industry in mainland China from 2018 to 2023 (unit: 100 million yuan, %)
Exhibit 87: Product structure of domestic medical device companies in 2023 (unit: %)
Exhibit 88: Competitive landscape of brands in the Chinese medical device market
Exhibit 89: 2018-2023 China Daily Chemical Market Sales Revenue Trend Chart (Unit: US$ 100 million, %)
Exhibit 90: List of well-known local daily chemical brands in China
Exhibit 91: Analysis of the horizontal expansion of Chinese pharmaceutical companies
Exhibit 92: Horizontal expansion of Chinese pharmaceutical companies
Exhibit 93: Overall profit distribution of China's cosmetics industry (unit: %)
Exhibit 94: Channel Distribution of China's Cosmetics Industry by Sales Revenue (Unit: %)
Exhibit 95: Distribution of Distribution Channels by Segment (by Sales Revenue) (Unit: %)
Exhibit 96: Nutraceuticals industry value chain
Exhibit 97: Advantages of Infinitus' Direct Selling Model
Exhibit 98: List of five e-commerce models in the healthcare sector
Exhibit 99: Analysis of the vertical expansion of Chinese pharmaceutical companies
Exhibit 100: Vertical expansion of Chinese pharmaceutical companies
Exhibit 101: China's Top 500 Top 10 Health Enterprises in 2023 (Unit: million yuan)
Exhibit 102: Distribution of the contribution rate of total sales of physical pharmacies by major categories in 2023 (unit: %)
Exhibit 103: Distribution of the contribution rate of total sales of each major category of online pharmacies in 2023 (unit: %)
Exhibit 104: Changes in the contribution rate of total sales of food/health products from 2019 to 2023 (unit: %)
Exhibit 105: Leading online layout of retail pharmacies in 2023
Exhibit 106: Basic information table of Yunnan Baiyao Group Co., Ltd
Exhibit 107: Shareholding structure of Yunnan Baiyao Group Co., Ltd. as of 2023 (unit: %)
Figure 108: Yunnan Baiyao Group Co., Ltd.'s short- and medium-term health strategy
Exhibit 109: Yunnan Baiyao Group Co., Ltd.'s medium- and long-term health strategy
Exhibit 110: 2023 Yunnan Baiyao Group Co., Ltd. Sales Area Distribution by Operating Income (Unit: %)
Figure 111: Yunnan Baiyao Group Co., Ltd. main products
Exhibit 112: Business structure of Yunnan Baiyao Group Co., Ltd. in 2023 (unit: 100 million yuan, %)
Exhibit 113: List of Yunnan Baiyao Group Co., Ltd.'s flagship health products
Figure 114: Analysis of main economic indicators of Yunnan Baiyao Group Co., Ltd. from 2019 to 2023 (unit: 10,000 yuan)
Exhibit 115: Profitability analysis of Yunnan Baiyao Group Co., Ltd. from 2019 to 2023 (unit: %)
Exhibit 116: Analysis of the operating capacity of Yunnan Baiyao Group Co., Ltd. from 2019 to 2023 (unit: times)
Exhibit 117: Solvency analysis of Yunnan Baiyao Group Co., Ltd., 2019-2023 (unit: %, times)
Exhibit 118: 2019-2023 Development Capability Analysis of Yunnan Baiyao Group Co., Ltd. (Unit: %)
Figure 119: Analysis of the advantages and disadvantages of Yunnan Baiyao Group Co., Ltd.'s big health strategy
Exhibit 120: Basic information table of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd
Abbreviation····